Ascend Capital’s Regeneron Pharmaceuticals REGN Stock Holding History

Ascend Capital’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q1	–	Sell	-3,000	Closed	-$1.1M	–	175
2016 Q4	$1.1M	Buy	+3,000	New	+$1.14M	0.05%	130
2016 Q3	–	Sell	-10,000	Closed	-$3.49M	–	154
2016 Q2	$3.49M	Sell	10,000 -15,000	-60%	-$5.78M	0.23%	104
2016 Q1	$9.01M	Buy	25,000 +12,301	+97%	+$5.07M	0.86%	50
2015 Q4	$6.89M	Buy	+12,699	New	+$6.88M	0.24%	92
2014 Q3	–	Sell	-15,081	Closed	-$4.26M	–	209
2014 Q2	$4.26M	Buy	+15,081	New	+$4.47M	0.14%	137

Other funds holding REGN

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Ascend Capital's REGN Position: Q1 2017 in Review

Ascend Capital sold out of Regeneron Pharmaceuticals (REGN) in Q1 2017, closing a stake of 3,000 shares — an estimated $1.1M sold.

Ascend Capital first reported a position in REGN in Q2 2014 and held it in 5 quarters. The position peaked at $9.01M in Q1 2016. 578 funds tracked by Wall St. Rank hold REGN as of Q1 2017.

Ascend Capital reported no remaining Regeneron Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
Ascend Capital sold 3,000 Regeneron Pharmaceuticals shares in Q1 2017, an estimated $1.1M.
Ascend Capital first reported a position in Regeneron Pharmaceuticals in Q2 2014 and held it in 5 quarters.
Ascend Capital's Regeneron Pharmaceuticals position peaked at $9.01M in Q1 2016.
578 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2017.

Based on Ascend Capital's 13F filing for Q1 2017, filed 15 May 2017.